comparemela.com

Latest Breaking News On - Arcutis biotherapeutics company profile - Page 5 : comparemela.com

Arcutis Biotherapeutics, Inc (NASDAQ:ARQT) Sees Large Growth in Short Interest

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Get Free Report) was the target of a large growth in short interest in the month of June. As of June 30th, there was short interest totalling 14,730,000 shares, a growth of 12.5% from the June 15th total of 13,090,000 shares. Based on an average daily trading volume, of 1,300,000 […]

Arcutis Biotherapeutics (NASDAQ:ARQT) Trading 6 6% Higher

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Get Free Report)’s share price traded up 6.6% during trading on Wednesday . The stock traded as high as $9.96 and last traded at $9.91. 253,737 shares changed hands during mid-day trading, a decline of 77% from the average session volume of 1,124,942 shares. The stock had previously closed at […]

Arcutis Biotherapeutics, Inc (NASDAQ:ARQT) Receives Average Rating of Buy from Brokerages

Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Free Report) have been assigned an average rating of “Buy” from the seven analysts that are covering the company, Marketbeat.com reports. Seven research analysts have rated the stock with a buy rating. The average 12 month price objective among brokers that have updated their coverage on the stock […]

Arcutis Biotherapeutics (NASDAQ:ARQT) Trading Down 3 4%

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Get Rating)’s stock price fell 3.4% during trading on Tuesday . The company traded as low as $8.13 and last traded at $8.27. 237,631 shares were traded during mid-day trading, a decline of 78% from the average session volume of 1,064,101 shares. The stock had previously closed at $8.56. Wall […]

Arcutis Biotherapeutics, Inc (NASDAQ:ARQT) Receives $46 83 Average Price Target from Analysts

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Get Rating) has been assigned a consensus rating of “Buy” from the seven research firms that are presently covering the company, Marketbeat.com reports. Seven investment analysts have rated the stock with a buy recommendation. The average 1 year target price among brokerages that have issued ratings on the stock in […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.